Gilead Sciences (GILD)

Health Care · $211B market cap · SEC CIK 0000882095

Next reports on Feb 8, 2027, after the close, with analysts expecting $1.22 in earnings per share.

52-week range $116.88 to $176.58. 3% below its 52-week high and 46% above its low.

The case for GILD

• Generated $9.5B of free cash flow in FY2025, 32% of revenue.
• Pays a 4.0% dividend while you wait.
• Gross margin of 80% absorbs cost shocks.
• Moves less than the market (beta 0.38).
• Within 3% of its 52-week high: the trend is up.
• Up 42.5% over the past year.

The case against

• Losing money over the last year: net margin −12.5%, return on equity −22%.
• Earnings per share down 20.2%.
• Priced at 24.8× earnings while earnings per share are shrinking (−20.2%).
• Priced at 6.8× sales with revenue growing only 6.5%.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• The P/E (24.8×) says it made money over the last year but its net margin (−12.5%) says it lost money, so the P/E is not counted in its favour.
• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Gilead Sciences's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Gilead Sciences says it does

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our Business Products We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens,…

Risk factors GILD lists in its 10-K

• Certain of our products subject us to additional or heightened risks
• Our success depends on developing and commercializing new products or expanding the indications for existing products
• We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories
• We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers
• Our existing products are subject to pricing and reimbursement pressures from government agencies and other third parties, including required discounts and rebates
• We may experience adverse impacts resulting from the importation of our products from lower price markets or the distribution of illegally diverted or counterfeit versions of our products
• We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption
• We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the healthcare industry
• We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations
• Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases
• We face risks associated with our global operations
• Climate change and related natural disasters, as well as legal, regulatory, or market measures to address climate change, can negatively affect our business and operations
• Our aspirations, goals and disclosures related to corporate responsibility matters expose us to numerous risks, including risks to our reputation and stock price
• Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us
• We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions
• Our U.S. manufacturing and R&D investments may not achieve their intended benefits and could adversely affect our business, results of operations and cash flows
• Changes in our effective income tax rate could reduce our earnings

Filings

Other Health Care companies